Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma.

But it’s also the way our health insurance system is set up.” The structure and overregulation of insurance has also played a part in inflating health care costs, he said. And consolidation ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial ...

Forest plots of daratumumab OS efficacy (vs. therapies without daratumumab) according to (A) low- and (B) high-physical function. The study analyzed data from 1,804 patients enrolled in three ...

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study ...

How cancer patients feel physically before beginning treatment with daratumumab can predict how long they will live and how well they will respond to this multiple myeloma therapy, according to ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti- multiple myeloma (MM ...

In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. Systemic ...

in favor of the benefit-risk profile of single-agent DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM).